Predictive factors of chemotherapy-induced oral mucositis in colorectal cancer: role of polymorphisms in genes mediating the inflammatory response

Authors

Catarina Rodrigues Serviço de Oncologia Médica - Centro Oncológico, CHTMAD, EPE
Carina Pereira Universidade do Porto, Porto
Rui Medeiros Universidade do Porto, Porto
Mário Dinis-Ribeiro C.I.N.T.E.S.I.S. – Serviço de Bioestatística e Informática Médica. Faculdade de Medicina do Porto, Porto

DOI:

https://doi.org/10.31877/on.2010.14.02

Keywords:

Oral mucositis, genetic polymorphisms, colorectal cancer, chemotherapy, inflammation

Abstract

From a consecutive series of colorectal cancer patients treated with chemotherapy (n=108), a case-control study was performed, to establish the role of genetic polymorphisms in genes modulating the inflammatory response in the evolution of oral mucositis (OM). However, other variables influencing the individual risk for oral mucositis were included for study. No differences are observed both in gender, mean age of participants, body mass index, diabetes mellitus, dental prosthesis, smoking, alcohol consumption and hematological data changes between cases and controls. Earlier OM was reported in a higher proportion of cases (35%) (vs 0% in controls, p≤0.001). The TNF-α -308A allele appeared to be associated with a decreased risk for oral mucositis onset (OR=0.266; 95%CI: 0.073-0.964) in colorectal cancer patients treated with chemotherapy. Further studies should be conducted as this may represent a risk marker for this important side-effect after chemotherapy, in a way that may enable to submit patients to preventive strategies and early diagnosis.

Downloads

Download data is not yet available.

References

Boyle, P., Langman, J.S., ABC of Colorectal Cancer: Epidemiology. BMJ 2000; 32:805-808.

Wolpin, B.M., Meyerhardt, J.A., et al., Adjuvant Treatment of Colorectal Cancer. CA A Cancer Journal for Clinicians 2007; 57:168-85.

Costa, C., Magalhães, H., et al., O Cancro e a Qualidade de vida – A Quimioterapia e outros Fármacos no combate ao Cancro. 1ª Edição,

Novartis Farma 2005. ISBN: 972-9119-94-5.

Fadda, G., Campus, G., et al., Risk factorsfor oral mucositisin paediatric oncology patientsreceiving alkylant chemotherapy. BMC Oral Health2006; 6(13): http://www.biomedcentral.com/1472-6831/6/13.

Pico, J.L., Avila-Garavito, A., et al., Mucositis: Its Occurence, Consequences, and Treatment in the Oncology Setting. The Oncologist

; 3:446-451.

Köstler, W.J., Hejna, M., et al., Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Optionsfor Prevention and

Treatment. CA Cancer J Clin 2001; 51(5):290-315.

Stone, R., Fliedner, M.C., et al., Management of oral mucositisin patients with cancer. European Journal of Oncology Nursing 2005; 9

Suppl 1:24-32.

Cheng, K.K., Oral mucositis, dysfunction, and distressin patients undergoing cancer therapy. Journal of Clinical Nursing 2007; 16(11):2114-21.

Peterson, D.E., Cariello Anna, Mucosal Damage: A Major Risk Factor for Severe Complications After Cytotoxic Therapy. Seminarsin Oncology 2004; 31(3):35-44.

Sonis, S.T., Elting, L.S., Perspectives on Cancer Therapy-Induced Mucosal Injury: Pathogenesis, Measurement, Epidemiology, and

Consequencesfor patients. Cancer Supplement 2004; 100(9):1995-2011.

Sonis, S.T., Pathobiology of Oral Mucositis: Novel insights and opportunities. J Support Oncol 2007; 5(9):3-11.

Zhang, X., Miao, X., et al., Identification of Functional Genetic Variants in Cyclooxygenase-2 and their Association with risk of Esophageal

Cancer. Gastroenterology 2005; 129:565-76.

Pereira, C.; Sousa, H.; Ferreira, P.; Fragoso, M.; Moreira-Dias, L.; Lopes C.; Medeiros, R.; Dinis-Ribeiro, M.; –765G >C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J. Gastroenterol.2006; 12:

-5478.

Kristiansen, O.P.; Nolsøe, R.L.; Larsen, L.; Gjesing, A.M.; Johannesen, J.; Larsen, Z.M.; Lykkesfeldt, A.E.; Karlsen, A.E.; Pociot, F.; Mandrup-Poulsen, T.; Association of a functional 17beta-estradiolsensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetesin

females. Hum. Mol. Genet. 2003; 12:1101-1110.

Whyte, M., Hubbard, R., et al., Increased risk of fibrosing alveolitis associated with Interleukin-1 receptor antagonist and tumor necrosis

factor-a gene polymorphisms. Am J RespCrit CareMed. 2000; 162:755-58.

Szczeklil,W., Sanak, M., et al., Functional effects and gender association of COX-2 gene polymorphism G-765Cin bronchial asthma. J Allergy Clin Immunol, 2004. 114(2):248-53.

Meyerhardt, J.A.; Catalano, P.J.; Haller, D.G.; Mayer, R.J.; Benson, A.B.; Macdonald, J.S.; Fuchs, C.S.; Influence of body massindex on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003; 98:484-495.

Meyerhardt, J.A.; Catalano, P.J.; Haller, D.G.; Mayer, R.J.; Macdonald, J.S.; Benson, A.B.; Fuchs, C.S.; Impact of diabetes mellitus on outcomes in patients with colon cancer. J. Clin. Oncol. 2003; 21: 433-440.

Sloan, J.A.; Loprinzi, C.L.; Novotny, P.J.; Okuno, S.; Nair, S.; Barton, D.L.; Sex Differencesin Fluorouracil-Induced Stomatitis. J. Clin. Oncol.

; 18:412-420.

McCarthy, G.M.; Awde, J.D.; Ghandi, H.; Vincent, M.; Kocha, W.I.; Risk factors associated with mucositisin cancerpatientsreceiving

-fluorouracil. Oral Oncol. 1998; 34:484-490.

Vatay, A., Bene, L., et al., Relationship between the tumor necrosis factor alpha polymorphisms and the serum C-reactive protein levelsin

inflammatory bowel disease. Immunogenetics 2003; 55:247-52.

Baran, W., Szepietowski, J.C., et al., A -308 promoter polymorphism of tumor necrosisfactor alpha gene does not associate with the

susceptibility to psoriasis vulgaris. No difference either between psoriasistype I and type II patients. Acta DermatovenAPA 2006;

(3):113-118.

Hall, P.D.; Benko, H.; Hogan, K.R.; Stuart, R.K.; The influence ofserum tumor necrosisfactor-alpha and interleukin-6 concentrations on

nonhematologic toxicity and hematologic recovery in patients with acute myelogenousleukaemia. Exp Hematol. 1995; 23:1256-60.

Logan, R.M.; Stringer, A.M.; Bowen, J.M.; Gibson, R.J.; Sonis, S.T.; Keefe, D.M.; Serum levels of NFkappaB and pro-inflammatory cytokines

following administration of mucotoxic drugs. Cancer Biol. Ther. 2008; 7:1139-1145.

Lima, V.; Brito, G.A.; Cunha, F.Q.; Rebouças, C.G.; Falcão, B.A.; Augusto, R.F.; Souza, M.L.; Leitão, B.T.; Ribeiro, R.A.; Effects of the tumour

necrosisfactor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositisin hamsters. Eur. J. Oral. Sci. 2005;

:210-217.

Guimarães, A.L., Correia-Silva, J.F., et al., Investigation of functional gene polymorphismsIL-1beta, IL-6, IL-10 and TNF-alpha in individuals

with recurrent aphthousstomatitis. Arch Oral Biol. 2007; 52(3):268-72.

Galbraith, G.M., Hendley, T.M., et al., Polymorphic cytokine genotypes as markers of disease severity in adult periodontitis. J Clin Periodontol. 1999; 26(11):705-9.

Shapira, L., Stabholz, A., et al., Genetic Polymorphism of the tumor necrosisfactor(TNF)-a promoter region in families with localized early-onset periodontitis. J Periodontal Res. 2001; 36(3):183-6.

Zheng, M.H.; Qiu, L.X.; Xin, Y.N.; Pan, H.F.; Shi, K.Q.; Chen, Y.P.; Tumor necrosisfactor-alpha-308A allele may have a protective effect for

chronic hepatitis B virusinfection in Mongoloid populations, Int. J. Infect. Dis. 2008;12:S62.

D. Gambhir D; Lawrence, A.; Aggarwal, A.; Misra, R.; Mandal, S.K.; Naik, S.; Association of tumor necrosisfactor alpha and IL-10 promoter

polymorphisms with rheumatoid arthritisin North Indian population. Rheumatol. Int. 2009.

Lalla, R.V.; Pilbeam, C.C.; Walsh, S.J.; Sonis, S.T.; Keefe, D.M.; Peterson, D.E.; Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilotstudy. Support Care Cancer 2009.

Lopes, N.N.; Plapler, H.; Chavantes, M.C.; Lalla, R.V.; Yoshimura, E.M.; Alves, M.T.; Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositisin hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer

; 17:1409-1415.

Zhang, X.; Miao, X.; Tan, W.; Ning, B.; Liu, Z.; Hong, Y.; et al.; Identification of functional genetic variantsin cyclooxygenase-2 and

their association with risk of esophageal cancer. Gastroenterology 2005; 129:565-576.

Zhao, D.; Xu, D.; Zhang, X.; Wang, L.; Tan, W.; Guo, Y.; et al.; Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a

possible role of nucleophosmin. Gastroenterology 2009; 136:1659-1668.

Ho, Y.P.; Lin, Y.C.; Yang, Y.H.; Ho, K.Y.; Wu, Y.M.; Tsai, C.C.; Cyclooxygenase-2 Gene-765 single nucleotide polymorphism as a

protective factor against periodontitisin Taiwanese. J Clin Periodontol, 2008; 35.

Xie, C.J.; Xiao, L.M.; Fan, W.H.; Xuan, D.Y.; Zhang J.C.; Common single nucleotide polymorphismsin cyclooxygenase-2 and risk ofsevere

chronic periodontitisin a Chinese population. J. Clin. Periodontol. 2009; 36:198-203.

Downloads

PDF (Português (Portugal))

Published

2010-09-10

How to Cite

Rodrigues C, Pereira C, Medeiros R, Dinis-Ribeiro M. Predictive factors of chemotherapy-induced oral mucositis in colorectal cancer: role of polymorphisms in genes mediating the inflammatory response. Onco.News [Internet]. 2010 Sep. 10 [cited 2024 Dec. 4];(14):18-25. Available from: https://onco.news/index.php/journal/article/view/221